NCT00267722View on ClinicalTrials.gov

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Crohn's Disease

Interventions

DRUG

Visilizumab

Trial Locations (2)

10029

Mount Sinai School of Medicine, New York

90048

Inflammatory Bowel Disease Center, Los Angeles

Sponsors

Lead Sponsor

Collaborators (1)

PDL BioPharma, Inc.

All Listed Sponsors

collaborator

PDL BioPharma, Inc.

INDUSTRY

lead

Facet Biotech

INDUSTRY

NCT00267722 - Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease | Biotech Hunter | Biotech Hunter